India’s medicines regulator, CDSCO, cancels the registration of FatX Solution after concluding the product is being marketed with fat-dissolving treatment claims. Both reports say the action follows regulatory review and results in the product no longer holding the registration status it previously had.

The outlets describe CDSCO’s concern as related to how the company presents FatX Solution. Business Line - Home says the regulator views the marketing as making drug-like claims, including treating “dissolving fat cells” and reducing their size. Times of India similarly frames the decision as regulatory trouble tied to the product’s fat-dissolving assertions, citing the cancellation of registration by CDSCO.

While the articles differ slightly in phrasing—one emphasising “misleading claims” and the other stressing “fat-dissolving claims”—they converge on the same outcome: CDSCO cancels FatX’s registration due to the claims associated with its marketing.